SCHEMBL15027017

SCHEMBL15027017

CCCCCCCCCC/C=C\COC(=O)CCCCCCCN(CCCCCCCC(=O)OC/C=C\CCCCCCCCCC)C(=O)CCCN(C)C

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 4/20 0.50
DNM1 Q05193 1/20 0.50
DGKA P23743 1/20 0.46
FAAH O00519 2/20 0.45
TSHR P16473 1/20 0.45
LPAR1 Q92633 5/20 0.45
ENPP2 Q13822 2/20 0.45
LPAR4 Q99677 2/20 0.45
LPAR5 Q9H1C0 2/20 0.45
LPAR2 Q9HBW0 2/20 0.45
LPAR3 Q9UBY5 2/20 0.45
CES2 O00748 1/20 0.45
LPAR6 P43657 1/20 0.45
TRPV1 Q8NER1 1/20 0.45
PRKCE Q02156 1/20 0.44
PRKCQ Q04759 1/20 0.44
PRKCD Q05655 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15027020 1.00 EPHX2 (0.50) EPHX2DNM1DGKAFAAHTSHR
SCHEMBL15026968 1.00 EPHX2 (0.50) EPHX2DNM1DGKAFAAHTSHR
SCHEMBL15026922 0.99 DNM1 (0.51) EPHX2DNM1DGKAFAAHTSHR
SCHEMBL21426280 0.94 DGKA (0.51) EPHX2DGKAFAAHTSHRLPAR1
SCHEMBL25788524 0.91 PRKCA (0.50) EPHX2DNM1DGKAFAAHLPAR1
SCHEMBL15027026 0.91 DNM1 (0.57) EPHX2DNM1DGKAFAAHLPAR1
SCHEMBL25788495 0.89 PRKCA (0.48) EPHX2DNM1DGKAFAAHLPAR1
SCHEMBL16172063 0.88 DNM1 (0.42) EPHX2DNM1DGKALPAR1PRKCE
SCHEMBL14239784 0.88 DNM1 (0.63) EPHX2DNM1DGKAFAAHLPAR1
SCHEMBL17586403 0.88 DNM1 (0.63) EPHX2DNM1DGKAFAAHLPAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140308304-A1 LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS ALNYLAM PHARMACEUTICALS, INC. 2014-10-16 US disclosed
US-20140308304-A1 LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS ALNYLAM PHARMACEUTICALS, INC. 2014-10-16 US disclosed
WO-2013086373-A1 LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS ALNYLAM PHARMACEUTICALS, INC. (US) 2013-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140308304-A1 LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS NPC1L1, NPC1, CETP EPHX2 2530/4885DNM1 241/4885DGKA 394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.